Bio & Pharma
ViGenCell obtains approval for HLA-B5801 genetic diagnostic kit for adverse reactions to gout treatment
The product is designed for compatibility, accuracy, and convenience, usable with most domestic hospital equipment
By Oct 25, 2024 (Gmt+09:00)
1
Min read
Most Read
Samsung Galaxy Z Fold Special Edition: slimmest, lightest of its kind
Bain Capital puts beauty device maker Classys on market
Doosan to resume Bobcat, Robotics merger with new ratio
Australia, Asia real estate whet Korean pension funds' appetite
Korea Zinc takes control of key shareholder in management feud with MBK
ViGenCell, a company specializing in immunotherapy, announced on Friday that it has obtained approval from the Ministry of Food and Drug Safety (MFDS) for its "ViGen HLA-B5801 RT Kit," a genetic test diagnostic kit for pre-screening to prevent adverse reactions to therapeutic agents in gout patients.
The newly approved product identifies the HLA-B5801 gene, which is linked to a high likelihood of severe cutaneous adverse drug reactions (SCARs) caused by the widely prescribed gout medication Allopurinol.
This diagnostic kit allows for pre-testing to prevent such adverse reactions by detecting the presence of the HLA-B5801 gene, which has been proven to be associated with SCARs.
In South Korea, the number of gout patients has risen by about 73% over the past decade, from 308,728 in 2014 to 535,100 in 2023, driven by changes in diet and lifestyle.
Allopurinol, a widely used treatment for gout, is the number one ingredient responsible for compensation for damage-related to adverse drug reactions and can cause long-term aftereffects.
Incidence of allopurinol-induced SCARs is related to the HLA-B5801 genotype, and the proportion of this genotype in Koreans is about 12%, which is higher than that of Westerners.
ViGenCell’s "ViGen HLA-B5801 RT Kit" is compatible with most equipment used in domestic hospitals and contract testing organizations.
The product employs the TaqMan Probe PCR method, which is performed by adding a fluorescent substance to a specific DNA sequence fragment of the target, and uses freeze-dried technology for enhanced accuracy and convenience.
Additionally, results can be easily verified using a dedicated viewer program.
“With the full insurance coverage of HLA-B5801 gene testing for patients requiring Allopurinol administration, the number of pre-tests will further increase. We are pleased to provide gout patients with the opportunity to choose safer treatment options along with genetic pre-diagnosis through the ‘ViGen HLA-B5801 RT Kit.,” said Choi Hee-baeg, Head of Business at ViGenCell.
Write to Woo-Sang Lee at idol@hankyung.com
More to Read
-
Bio & PharmaViGenCell, NK/T cell lymphoma treatment ‘VT-EBV-N’ designated as orphan drug in Europe
Dec 27, 2023 (Gmt+09:00)
2 Min read
Comment 0
LOG IN